お電話でもお問い合わせください
 03-5860-2441
Report thumbnail
商品コード AM091101248835
出版日 2024/1/10
Allied Market Research
英文391 ページグローバル

IVD（体外診断）市場 - 製品別、サービス別、技術別、用途別、エンドユーザー別：グローバルでの市場機会分析と業界予測、2023年〜2032年

In Vitro Diagnostics Market By Product and Services (Reagents and Kits, Instruments, Software and Services), By Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, Others), By Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, Others), By End User (Standalone Laboratories, Hospitals, Academic and Medical Schools, Point of Care, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032


Report thumbnail
商品コード AM091101248835◆2025年1月版も出版されている時期ですので、お問い合わせ後すぐに確認いたします。
出版日 2024/1/10
Allied Market Research
英文 391 ページグローバル

IVD（体外診断）市場 - 製品別、サービス別、技術別、用途別、エンドユーザー別：グローバルでの市場機会分析と業界予測、2023年〜2032年

In Vitro Diagnostics Market By Product and Services (Reagents and Kits, Instruments, Software and Services), By Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, Others), By Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, Others), By End User (Standalone Laboratories, Hospitals, Academic and Medical Schools, Point of Care, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032


全体要約

IVD市場は2022年に925億ドルと評価され、2032年には1384億ドルに達すると見込まれています。この10年間の年平均成長率（CAGR）は4.1%です。IVDは、血液や尿、組織などの検体を分析するための試験で、主に果たす役割は病気や感染症の早期発見です。関連する技術には、臨床化学、組織診断、免疫診断、分子診断などが含まれています。特に、慢性疾患の増加や早期診断の重要性の認識が市場成長を後押ししています。

市場は、製品・サービス、技術、用途、エンドユーザー、地域に分かれています。主要なプレイヤーには、F. Hoffmann-La Roche Ltd.やThermo Fisher Scientific, Inc.などがあり、製品の発売や提携を通じて市場シェアを拡大しようとしています。市場の成長を妨げる要因としては、熟練した技術者の不足が挙げられますが、DNAシーケンシングの技術革新が新たな機会を提供しています。

関連する質問

925億ドル（2022年）

4.1%（2023年から2032年）

Freenome Holdings, Inc., Invitae Corporation, Natera, Inc., Agilent Technologies, Inc., Exact Sciences Corporation, Guardant Health, Illumina, Inc., InterVenn Biosciences, NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc.

慢性疾患の有病率の増加、早期病気診断の重要性に対する意識の高まり、技術革新と個別化医療の推進。

概要

体外診断市場は2022年に925億ドルと評価され、2032年までに1384億ドルに達すると推定され、2023年から2032年までの間に年平均成長率（CAGR）は4.1％となる見込みです。体外診断（IVD）とは、病気、状態、感染症を検出するための検査です。体外とは、これらの検査が通常、試験管や類似の機器で実施されることを示し、生体内で行われる生体内検査とは対照的です。体外診断（IVD）には、血液、尿、便、組織、さまざまな体液などの検体を検査するために使用される試薬、器具、ソフトウェア、サービスなど、幅広いツールと技術が含まれます。これらの診断ツールは、病気、状態、感染症を検出するために不可欠です。IVD検査は、独立した研究所、病院ベースの施設、ポイントオブケアセンターなど、さまざまな場所で実施されています。
さらに、体外診断技術は、臨床化学、組織診断、免疫診断、 hematology（血液学）などの広範な方法論を含んでいます。たとえば、甲状腺機能検査は、患者からの血液を採取し、その血中の甲状腺刺激ホルモン（TSH）レベルを測定することで行われます。この検査は、甲状腺機能を評価するための重要なツールです。さらに、ポリメラーゼ連鎖反応（PCR）などの技術を使用して、HIV、肝炎、およびその他の感染症の存在を特定します。体外診断市場の成長は、心血管障害、癌、感染症などの慢性疾患の有病率の増加、早期疾病診断の重要性に対する認識の高まり、および新しい検査の導入の増加によって大きく推進されています。たとえば、アメリカ癌学会（ACS）によると、2023年には米国で約190万件の新しい癌ケースが診断されると予想されています。したがって、慢性疾患の有病率の上昇は、体外診断検査の需要を促進しています。
さらに、一般市民の間で早期病気診断に関する意識が高まったことにより、体外診断（IVD）の需要が増加しています。意識向上キャンペーン、教育セミナー、トレーニングプログラムは、早期病気診断の重要性を強調しています。例えば、F. ホフマン・ラ・ロッシュ社は、がん、肝炎、結核、HIV、HPV、心血管疾患などの病気に対するスクリーニングプログラムやカウンセリングプログラムを実施するために、地域のコミュニティパートナーを支援しています。また、IVD製品、サービスデザイン、技術における新たな革新が進行中であり、医師や研究者は従来の診断アプローチから個別化医療へと重点を移しています。この変化は、医療治療や介入を個々の患者のニーズや特性に合わせることの利点に対する認識が高まっていることを反映しており、市場の成長を後押ししています。
しかし、熟練したラボ技術者の不足が予測期間中の市場成長を妨げると予想されています。しかし、診断テストの数の増加とDNAシーケンシングの技術革新は、予測期間中の市場成長にとって有利な機会を生み出すと期待されています。
in vitro診断市場は、製品とサービス、技術、アプリケーション、エンドユーザー、および地域にセグメント化されています。製品とサービスによって、市場は試薬とキット、機器、ソフトウェアおよびサービスに分類されています。
技術別に、市場は免疫診断、血液学、分子診断、組織診断、臨床化学及びその他に分かれています。用途別に、市場は感染症、癌、心臓疾患、免疫系障害、腎臓疾患、消化器疾患及びその他に分類されます。最終ユーザー別に、市場はスタンドアロンラボ、病院、学術及び医療学校、ポイントオブケア及びその他に分類されています。地域別に、市場は北アメリカ（米国、カナダ、メキシコ）、ヨーロッパ（ドイツ、フランス、英国、イタリア、スペイン及びその他のヨーロッパ）、アジア太平洋（中国、日本、オーストラリア、インド、韓国及びその他のアジア太平洋）、そしてLAMEA（ブラジル、南アフリカ、サウジアラビア及びその他のLAMEA）で分析されています。
グローバル体外診断市場で活動している主要なキープレイヤーは、Freenome Holdings, Inc.、Invitae Corporation、Natera, Inc.、Agilent Technologies, Inc.、Exact Sciences Corporation、Guardant Health、Illumina, Inc.、InterVenn Biosciences、NeoGenomics Laboratories、F. Hoffmann-La Roche Ltd.、およびThermo Fisher Scientific, Inc.です。市場で活動しているキープレイヤーは、市場シェアと製品ポートフォリオを拡大するために、製品の発売、買収、パートナーシップ、製品承認、拡張を主要な戦略として採用しています。
ステークホルダーへの主要な利点
この報告書は、2022年から2032年までの体外診断市場分析の市場セグメント、現在のトレンド、推定値、およびダイナミクスに関する定量的分析を提供し、存在する体外診断市場の機会を特定します。
●市場調査は、主要なドライバー、制約、機会に関連する情報とともに提供されます。
ポーターのファイブフォース分析は、バイヤーとサプライヤーの影響力を明らかにし、利害関係者が利益志向のビジネス判断を行い、サプライヤーとバイヤーのネットワークを強化するのを可能にします。
in vitro診断市場のセグメンテーションの詳細分析は、存在する市場機会を特定するのに役立ちます。
●各地域の主要国は、世界市場への収益貢献に基づいてマッピングされています。
市場プレイヤーのポジショニングはベンチマークを容易にし、市場プレイヤーの現在の位置を明確に理解することを可能にします。
この報告書には、地域およびグローバルな体外診断市場の動向、主要プレーヤー、市場セグメント、用途分野、市場成長戦略の分析が含まれています。
この購入で得られる追加の特典は：
● 四半期の更新および* (企業ライセンスがある場合にのみ、掲載価格で利用可能)
● 購入前または購入後のクライアントの選択による追加の会社プロフィール5件、無料のアップデートとして。
● 五つのライセンスおよびエンタープライズユーザーライセンス購入での無料の次期バージョン。
● 16時間のアナリストサポート*（購入後、レポートのレビュー中に追加のデータ要件が見つかった場合、質問を解決するために16時間のアナリストサポートを受けることができます。また、販売後の問い合わせにも対応します）
● 15% 無料カスタマイズ*（レポートの範囲やセグメントがご要件に合わない場合、15%は無料作業3営業日に相当し、一度のみ適用されます）
● ファイブおよびエンタープライズユーザーライセンスに関する無料データパック。（レポートのExcelバージョン）
● 6-12ヶ月以上古いレポートの場合、無料更新レポート。
● 24時間優先対応*
● 無料の業界最新情報とホワイトペーパー。
このレポートのカスタマイズが可能です（追加費用とタイムラインについては、営業担当者にお問い合わせください）。
● 規制ガイドライン
● クライアントの関心に特化した追加会社プロフィール
● 追加の国または地域分析 - 市場規模と予測
● 企業プロフィールの拡張リスト
歴史的市場データ
● SWOT分析
主要市場セグメント
エンドユーザー別
● スタンドアロンラボラトリーズ
● 病院
● 学術および医療学校
● ポイントオブケア
● その他
製品およびサービス別
試薬とキット
● 機器
● ソフトウェアとサービス
技術別
分子診断
組織診断
● 臨床化学
その他
免疫診断法
● 血液学
用途別
感染症
● がん
心臓病
免疫系障害
● 腎臓病
● 胃腸疾患
● その他
地域別
● 北米
アメリカ合衆国
○ カナダ
メキシコ
● ヨーロッパ
ドイツ
○ フランス
イギリス
○ イタリア
○ スペイン
残りのヨーロッパ
アジア太平洋
日本
中国
○ インド
オーストラリア
南韓
○ その他のアジア太平洋地域
● LAMEA
ブラジル
○ サウジアラビア
南アフリカ
○ その他のLAMEA
主要市場プレーヤー
インターヴェン バイオサイエンシズ
○ アジレント・テクノロジーズ社
○ イリュミナ社
○ サーモフィッシャーサイエンティフィック社
ネオジェノミクスラボラトリーズ
エグザクト・サイエンシズ・コーポレーション
○ フリーノーム・ホールディングス株式会社
○ ナテラ株式会社
○ F. ホフマン・ラ・ロシュ社
○ ガーダント・ヘルス
○ インビテック社

※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。

目次

  • 1 イントロダクション

    • 1.1 レポート概要
    • 1.2 主要な市場セグメント
    • 1.3 ステークホルダーにとっての有用なポイント
    • 1.4 調査手法
      • 1.4.1 一次調査
      • 1.4.2 二次調査
      • 1.4.3 アナリストのツール及びモデル

  • 2 エグゼクティブサマリー

    • 2.1 CXOの視点

  • 3 市場概要

    • 3.1 市場の定義と範囲
    • 3.2 主な調査結果
      • 3.2.1 影響を与える主な要因
      • 3.2.2 主な投資ポケット
    • 3.3 ポーターのファイブフォース分析
      • 3.3.1 中程度のサプライヤー交渉力
      • 3.3.2 中程度の新規参入脅威
      • 3.3.3 中程度の代替品脅威
      • 3.3.4 中程度の競合度合い
      • 3.3.5 高い買い手交渉力
    • 3.4 市場ダイナミクス
      • 3.4.1 促進要因
        • 3.4.1.1 慢性疾患および感染症の蔓延の増加
        • 3.4.1.2 病気の早期診断と個別化医療に対する意識の高まり
        • 3.4.1.3 診断検査機関数の増加
      • 3.4.2 抑制要因
        • 3.4.2.1 厳格な規制政策
      • 3.4.3 市場機会
        • 3.4.3.1 IVDにおける技術的向上

  • 4 IVD市場、製品およびサービス別

    • 4.1 概要
      • 4.1.1 市場規模・予測
    • 4.2 試薬・キット
    • 4.3 インスツルメンツ
    • 4.4 ソフトウェア・サービス

  • 5 IVDの市場、技術別

    • 5.1 概要
      • 5.1.1 市場規模・予測
    • 5.2 免疫診断
    • 5.3 ヘマトロジー
    • 5.4 分子診断
    • 5.5 組織診断
    • 5.6 クリニカルケミストリー
    • 5.7 その他

  • 6 IVDの市場、用途別

    • 6.1 概要
      • 6.1.1 市場規模・予測
    • 6.2 感染症
    • 6.3 がん
    • 6.4 心臓疾患
    • 6.5 免疫系疾患
    • 6.6 腎臓疾患
    • 6.7 消化器系疾患
    • 6.8 その他

  • 7 IVDの市場、エンドユーザー別

    • 7.1 概要
      • 7.1.1 市場規模・予測
    • 7.2 スタンドアローン研究ラボ
    • 7.3 病院
    • 7.4 大学・医学部
    • 7.5 ポイント・オブ・ケア
    • 7.6 その他

  • 8 IVDの市場、地域別

    • 8.1 概要
      • 8.1.1 市場規模・予測、地域別
    • 8.2 北米
    • 8.3 ヨーロッパ
    • 8.4 アジア太平洋
    • 8.5 ラテンアメリカ・中東・アフリカ

  • 9 競合情勢

    • 9.1 イントロダクション
    • 9.2 主な成功戦略
    • 9.3 Product mapping of top 10 player
    • 9.4 競合ダッシュボード
    • 9.5 競合ヒートマップ
    • 9.6 Top player positioning, 2022

  • 10 企業プロファイル

    • 10.1 Freenome Holdings, Inc
      • 10.1.1 企業概要
      • 10.1.2 主なエグゼクティブ
      • 10.1.3 企業情報
      • 10.1.4 事業セグメント
      • 10.1.5 製品ポートフォリオ
      • 10.1.6 主要な戦略的動向と展開
    • 10.2 Natera, Inc
    • 10.3 Agilent Technologies, Inc
    • 10.4 Exact Sciences Corporation
    • 10.5 Illumina, Inc
    • 10.6 F. Hoffmann-La Roche Ltd
    • 10.7 Guardant Health
    • 10.8 InterVenn Biosciences
    • 10.9 Thermo Fisher Scientific, Inc
    • 10.10 Invitae Corporation
    • 10.11 NeoGenomics Laboratories

※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”

Description

The in vitro diagnostics market was valued at $92.5 billion in 2022 and is estimated to reach $138.4 billion by 2032, exhibiting a CAGR of 4.1% from 2023 to 2032. In vitro diagnostics (IVDs) are tests that detect diseases, conditions, and infections. In vitro means these tests are typically conducted in test tubes and similar equipment, as opposed to in vivo tests, which are conducted in the body itself. In vitro diagnostics (IVD) includes a wide range of tools and techniques, including reagents, instruments, software, and services utilized for the examination of specimens such as blood, urine, stool, tissues, and various human body fluids. These diagnostic tools are essential for detecting diseases, conditions, and infections. IVD tests are conducted in various settings, including standalone laboratories, hospital-based facilities, and point of care centers.  In addition, in vitro diagnostic techniques encompass a broad array of methodologies, including clinical chemistry, tissue diagnostics, immunodiagnostics, hematology, and more. For instance, a thyroid function test involves the collection of blood from a patient, which is then analyzed to determine the level of thyroid-stimulating hormone (TSH) in the bloodstream. This test serves as a critical tool in assessing thyroid function. Furthermore, techniques such as polymerase chain reaction (PCR) are employed to identify the presence of infectious diseases such as HIV, hepatitis, and various others. The in vitro diagnostics market growth is significantly driven by increase in the prevalence of chronic diseases such as cardiovascular disorders, cancer, and infectious diseases, surge in awareness about importance of early disease diagnosis, and increase in new test launches, thus fueling the demand for IVD tests for early detection, monitoring, and management. For instance, according to American Cancer Society (ACS), about 1.9 million new cancer cases are expected to be diagnosed in the U.S. in 2023. Thus, rise in prevalence of chronic diseases drives the demand for in vitro diagnostic tests.  In addition, surge in awareness about early disease diagnosis among the general population has increased the demand for in vitro diagnostics. Awareness campaigns, educational seminars, and training programs emphasize the importance of early disease diagnosis. For instance, F. Hoffmann-La Roche Ltd., supports local community partners to run screening programs and counselling programs for diseases such as cancers, hepatitis, tuberculosis, HIV, HPV, and cardiovascular disease. Moreover, ongoing innovations in IVD products, service designs, and technology have prompted doctors and researchers to transition their emphasis away from conventional diagnostic approaches toward personalized medicine. This shift reflects a growing recognition of the benefits of tailoring medical treatments and interventions to individual patient needs and characteristics, which support the market growth.  However, lack of skilled laboratory technicians is anticipated to hinder the market growth during the forecast period. However, rise in the number of diagnostic testing and technological advancements in DNA sequencing are expected to create lucrative opportunities for the market growth during the forecast period. The in vitro diagnostics market is segmented into product & services, technique, application, end user, and region. By product & services, the market is categorized into reagents & kits, instruments, and software & services.  By technique, the market is divided into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. By application, the market is classified into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. By end user, the market is classified into standalone laboratories, hospitals, academic and medical schools, point of care, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).  Major key players that operate in the global in vitro diagnostics market are Freenome Holdings, Inc., Invitae Corporation, Natera, Inc., Agilent Technologies, Inc., Exact Sciences Corporation, Guardant Health, Illumina, Inc., InterVenn Biosciences, NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific, Inc. Key players operating in the market have adopted product launch, acquisition, partnership, product approval, and expansion as key strategies to expand their market share and product portfolio. Key Benefits for Stakeholders ●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the in vitro diagnostics market analysis from 2022 to 2032 to identify the prevailing in vitro diagnostics market opportunities. ●The market research is offered along with information related to key drivers, restraints, and opportunities. ●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network. ●In-depth analysis of the in vitro diagnostics market segmentation assists to determine the prevailing market opportunities. ●Major countries in each region are mapped according to their revenue contribution to the global market. ●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players. ●The report includes the analysis of the regional as well as global in vitro diagnostics market trends, key players, market segments, application areas, and market growth strategies. Additional benefits you will get with this purchase are: ● Quarterly Update and* (only available with a corporate license, on listed price) ● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update. ● Free Upcoming Version on the Purchase of Five and Enterprise User License. ● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries) ● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once) ● Free data Pack on the Five and Enterprise User License. (Excel version of the report) ● Free Updated report if the report is 6-12 months old or older. ● 24-hour priority response* ● Free Industry updates and white papers. Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more) ● Regulatory Guidelines ● Additional company profiles with specific to client's interest ● Additional country or region analysis- market size and forecast ● Expanded list for Company Profiles ● Historic market data ● SWOT Analysis Key Market Segments By End User ● Standalone Laboratories ● Hospitals ● Academic and Medical Schools ● Point of Care ● Others By Product and Services ● Reagents and Kits ● Instruments ● Software and Services By Technique ● Molecular Diagnostics ● Tissue Diagnostics ● Clinical Chemistry ● Others ● Immunodiagnostics ● Hematology By Application ● Infectious Diseases ● Cancer ● Cardiac Diseases ● Immune System Disorders ● Nephrological Diseases ● Gastrointestinal Diseases ● Others By Region ● North America ○ U.S. ○ Canada ○ Mexico ● Europe ○ Germany ○ France ○ UK ○ Italy ○ Spain ○ Rest of Europe ● Asia-Pacific ○ Japan ○ China ○ India ○ Australia ○ South Korea ○ Rest of Asia-Pacific ● LAMEA ○ Brazil ○ Saudi Arabia ○ South Africa ○ Rest of LAMEA ● Key Market Players ○ InterVenn Biosciences ○ Agilent Technologies, Inc. ○ Illumina, Inc. ○ Thermo Fisher Scientific, Inc. ○ NeoGenomics Laboratories ○ Exact Sciences Corporation ○ Freenome Holdings, Inc. ○ Natera, Inc. ○ F. Hoffmann-La Roche Ltd. ○ Guardant Health ○ Invitae Corporation

Table of Contents

  • 1 INTRODUCTION

    • 1.1 Report description
    • 1.2 Key market segments
    • 1.3 Key benefits to the stakeholders
    • 1.4 Research methodology
      • 1.4.1 Primary research
      • 1.4.2 Secondary research
      • 1.4.3 Analyst tools and models

  • 2 EXECUTIVE SUMMARY

    • 2.1 CXO Perspective

  • 3 MARKET OVERVIEW

    • 3.1 Market definition and scope
    • 3.2 Key findings
      • 3.2.1 Top impacting factors
      • 3.2.2 Top investment pockets
    • 3.3 Porter’s five forces analysis
      • 3.3.1 Moderate bargaining power of suppliers
      • 3.3.2 Moderate threat of new entrants
      • 3.3.3 Moderate threat of substitutes
      • 3.3.4 Moderate intensity of rivalry
      • 3.3.5 High bargaining power of buyers
    • 3.4 Market dynamics
      • 3.4.1 Drivers
        • 3.4.1.1 Increase in prevalence of chronic and infectious diseases
        • 3.4.1.2 Surge in awareness about early disease diagnosis and personalized medicine
        • 3.4.1.3 Rise in number of diagnostic laboratories
      • 3.4.2 Restraints
        • 3.4.2.1 Stringent regulatory policies
      • 3.4.3 Opportunities
        • 3.4.3.1 Technological advancements in IVD

  • 4 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES

    • 4.1 Overview
      • 4.1.1 Market size and forecast
    • 4.2 Reagents and Kits
      • 4.2.1 Key market trends, growth factors and opportunities
      • 4.2.2 Market size and forecast, by region
      • 4.2.3 Market share analysis by country
    • 4.3 Instruments
      • 4.3.1 Key market trends, growth factors and opportunities
      • 4.3.2 Market size and forecast, by region
      • 4.3.3 Market share analysis by country
    • 4.4 Software and Services
      • 4.4.1 Key market trends, growth factors and opportunities
      • 4.4.2 Market size and forecast, by region
      • 4.4.3 Market share analysis by country

  • 5 IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

    • 5.1 Overview
      • 5.1.1 Market size and forecast
    • 5.2 Immunodiagnostics
      • 5.2.1 Key market trends, growth factors and opportunities
      • 5.2.2 Market size and forecast, by region
      • 5.2.3 Market share analysis by country
    • 5.3 Hematology
      • 5.3.1 Key market trends, growth factors and opportunities
      • 5.3.2 Market size and forecast, by region
      • 5.3.3 Market share analysis by country
    • 5.4 Molecular Diagnostics
      • 5.4.1 Key market trends, growth factors and opportunities
      • 5.4.2 Market size and forecast, by region
      • 5.4.3 Market share analysis by country
    • 5.5 Tissue Diagnostics
      • 5.5.1 Key market trends, growth factors and opportunities
      • 5.5.2 Market size and forecast, by region
      • 5.5.3 Market share analysis by country
    • 5.6 Clinical Chemistry
      • 5.6.1 Key market trends, growth factors and opportunities
      • 5.6.2 Market size and forecast, by region
      • 5.6.3 Market share analysis by country
    • 5.7 Others
      • 5.7.1 Key market trends, growth factors and opportunities
      • 5.7.2 Market size and forecast, by region
      • 5.7.3 Market share analysis by country

  • 6 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION

    • 6.1 Overview
      • 6.1.1 Market size and forecast
    • 6.2 Infectious Diseases
      • 6.2.1 Key market trends, growth factors and opportunities
      • 6.2.2 Market size and forecast, by region
      • 6.2.3 Market share analysis by country
    • 6.3 Cancer
      • 6.3.1 Key market trends, growth factors and opportunities
      • 6.3.2 Market size and forecast, by region
      • 6.3.3 Market share analysis by country
    • 6.4 Cardiac Diseases
      • 6.4.1 Key market trends, growth factors and opportunities
      • 6.4.2 Market size and forecast, by region
      • 6.4.3 Market share analysis by country
    • 6.5 Immune System Disorders
      • 6.5.1 Key market trends, growth factors and opportunities
      • 6.5.2 Market size and forecast, by region
      • 6.5.3 Market share analysis by country
    • 6.6 Nephrological Diseases
      • 6.6.1 Key market trends, growth factors and opportunities
      • 6.6.2 Market size and forecast, by region
      • 6.6.3 Market share analysis by country
    • 6.7 Gastrointestinal Diseases
      • 6.7.1 Key market trends, growth factors and opportunities
      • 6.7.2 Market size and forecast, by region
      • 6.7.3 Market share analysis by country
    • 6.8 Others
      • 6.8.1 Key market trends, growth factors and opportunities
      • 6.8.2 Market size and forecast, by region
      • 6.8.3 Market share analysis by country

  • 7 IN VITRO DIAGNOSTICS MARKET, BY END USER

    • 7.1 Overview
      • 7.1.1 Market size and forecast
    • 7.2 Standalone Laboratories
      • 7.2.1 Key market trends, growth factors and opportunities
      • 7.2.2 Market size and forecast, by region
      • 7.2.3 Market share analysis by country
    • 7.3 Hospitals
      • 7.3.1 Key market trends, growth factors and opportunities
      • 7.3.2 Market size and forecast, by region
      • 7.3.3 Market share analysis by country
    • 7.4 Academic and Medical Schools
      • 7.4.1 Key market trends, growth factors and opportunities
      • 7.4.2 Market size and forecast, by region
      • 7.4.3 Market share analysis by country
    • 7.5 Point of Care
      • 7.5.1 Key market trends, growth factors and opportunities
      • 7.5.2 Market size and forecast, by region
      • 7.5.3 Market share analysis by country
    • 7.6 Others
      • 7.6.1 Key market trends, growth factors and opportunities
      • 7.6.2 Market size and forecast, by region
      • 7.6.3 Market share analysis by country

  • 8 IN VITRO DIAGNOSTICS MARKET, BY REGION

    • 8.1 Overview
      • 8.1.1 Market size and forecast By Region
    • 8.2 North America
      • 8.2.1 Key market trends, growth factors and opportunities
      • 8.2.2 Market size and forecast, by Product and Services
      • 8.2.3 Market size and forecast, by Technique
      • 8.2.4 Market size and forecast, by Application
      • 8.2.5 Market size and forecast, by End User
      • 8.2.6 Market size and forecast, by country
        • 8.2.6.1 U.S
          • 8.2.6.1.1 Market size and forecast, by Product and Services
          • 8.2.6.1.2 Market size and forecast, by Technique
          • 8.2.6.1.3 Market size and forecast, by Application
          • 8.2.6.1.4 Market size and forecast, by End User
        • 8.2.6.2 Canada
          • 8.2.6.2.1 Market size and forecast, by Product and Services
          • 8.2.6.2.2 Market size and forecast, by Technique
          • 8.2.6.2.3 Market size and forecast, by Application
          • 8.2.6.2.4 Market size and forecast, by End User
        • 8.2.6.3 Mexico
          • 8.2.6.3.1 Market size and forecast, by Product and Services
          • 8.2.6.3.2 Market size and forecast, by Technique
          • 8.2.6.3.3 Market size and forecast, by Application
          • 8.2.6.3.4 Market size and forecast, by End User
    • 8.3 Europe
      • 8.3.1 Key market trends, growth factors and opportunities
      • 8.3.2 Market size and forecast, by Product and Services
      • 8.3.3 Market size and forecast, by Technique
      • 8.3.4 Market size and forecast, by Application
      • 8.3.5 Market size and forecast, by End User
      • 8.3.6 Market size and forecast, by country
        • 8.3.6.1 Germany
          • 8.3.6.1.1 Market size and forecast, by Product and Services
          • 8.3.6.1.2 Market size and forecast, by Technique
          • 8.3.6.1.3 Market size and forecast, by Application
          • 8.3.6.1.4 Market size and forecast, by End User
        • 8.3.6.2 France
          • 8.3.6.2.1 Market size and forecast, by Product and Services
          • 8.3.6.2.2 Market size and forecast, by Technique
          • 8.3.6.2.3 Market size and forecast, by Application
          • 8.3.6.2.4 Market size and forecast, by End User
        • 8.3.6.3 UK
          • 8.3.6.3.1 Market size and forecast, by Product and Services
          • 8.3.6.3.2 Market size and forecast, by Technique
          • 8.3.6.3.3 Market size and forecast, by Application
          • 8.3.6.3.4 Market size and forecast, by End User
        • 8.3.6.4 Italy
          • 8.3.6.4.1 Market size and forecast, by Product and Services
          • 8.3.6.4.2 Market size and forecast, by Technique
          • 8.3.6.4.3 Market size and forecast, by Application
          • 8.3.6.4.4 Market size and forecast, by End User
        • 8.3.6.5 Spain
          • 8.3.6.5.1 Market size and forecast, by Product and Services
          • 8.3.6.5.2 Market size and forecast, by Technique
          • 8.3.6.5.3 Market size and forecast, by Application
          • 8.3.6.5.4 Market size and forecast, by End User
        • 8.3.6.6 Rest of Europe
          • 8.3.6.6.1 Market size and forecast, by Product and Services
          • 8.3.6.6.2 Market size and forecast, by Technique
          • 8.3.6.6.3 Market size and forecast, by Application
          • 8.3.6.6.4 Market size and forecast, by End User
    • 8.4 Asia-Pacific
      • 8.4.1 Key market trends, growth factors and opportunities
      • 8.4.2 Market size and forecast, by Product and Services
      • 8.4.3 Market size and forecast, by Technique
      • 8.4.4 Market size and forecast, by Application
      • 8.4.5 Market size and forecast, by End User
      • 8.4.6 Market size and forecast, by country
        • 8.4.6.1 Japan
          • 8.4.6.1.1 Market size and forecast, by Product and Services
          • 8.4.6.1.2 Market size and forecast, by Technique
          • 8.4.6.1.3 Market size and forecast, by Application
          • 8.4.6.1.4 Market size and forecast, by End User
        • 8.4.6.2 China
          • 8.4.6.2.1 Market size and forecast, by Product and Services
          • 8.4.6.2.2 Market size and forecast, by Technique
          • 8.4.6.2.3 Market size and forecast, by Application
          • 8.4.6.2.4 Market size and forecast, by End User
        • 8.4.6.3 India
          • 8.4.6.3.1 Market size and forecast, by Product and Services
          • 8.4.6.3.2 Market size and forecast, by Technique
          • 8.4.6.3.3 Market size and forecast, by Application
          • 8.4.6.3.4 Market size and forecast, by End User
        • 8.4.6.4 Australia
          • 8.4.6.4.1 Market size and forecast, by Product and Services
          • 8.4.6.4.2 Market size and forecast, by Technique
          • 8.4.6.4.3 Market size and forecast, by Application
          • 8.4.6.4.4 Market size and forecast, by End User
        • 8.4.6.5 South Korea
          • 8.4.6.5.1 Market size and forecast, by Product and Services
          • 8.4.6.5.2 Market size and forecast, by Technique
          • 8.4.6.5.3 Market size and forecast, by Application
          • 8.4.6.5.4 Market size and forecast, by End User
        • 8.4.6.6 Rest of Asia-Pacific
          • 8.4.6.6.1 Market size and forecast, by Product and Services
          • 8.4.6.6.2 Market size and forecast, by Technique
          • 8.4.6.6.3 Market size and forecast, by Application
          • 8.4.6.6.4 Market size and forecast, by End User
    • 8.5 LAMEA
      • 8.5.1 Key market trends, growth factors and opportunities
      • 8.5.2 Market size and forecast, by Product and Services
      • 8.5.3 Market size and forecast, by Technique
      • 8.5.4 Market size and forecast, by Application
      • 8.5.5 Market size and forecast, by End User
      • 8.5.6 Market size and forecast, by country
        • 8.5.6.1 Brazil
          • 8.5.6.1.1 Market size and forecast, by Product and Services
          • 8.5.6.1.2 Market size and forecast, by Technique
          • 8.5.6.1.3 Market size and forecast, by Application
          • 8.5.6.1.4 Market size and forecast, by End User
        • 8.5.6.2 Saudi Arabia
          • 8.5.6.2.1 Market size and forecast, by Product and Services
          • 8.5.6.2.2 Market size and forecast, by Technique
          • 8.5.6.2.3 Market size and forecast, by Application
          • 8.5.6.2.4 Market size and forecast, by End User
        • 8.5.6.3 South Africa
          • 8.5.6.3.1 Market size and forecast, by Product and Services
          • 8.5.6.3.2 Market size and forecast, by Technique
          • 8.5.6.3.3 Market size and forecast, by Application
          • 8.5.6.3.4 Market size and forecast, by End User
        • 8.5.6.4 Rest of LAMEA
          • 8.5.6.4.1 Market size and forecast, by Product and Services
          • 8.5.6.4.2 Market size and forecast, by Technique
          • 8.5.6.4.3 Market size and forecast, by Application
          • 8.5.6.4.4 Market size and forecast, by End User

  • 9 COMPETITIVE LANDSCAPE

    • 9.1 Introduction
    • 9.2 Top winning strategies
    • 9.3 Product mapping of top 10 player
    • 9.4 Competitive dashboard
    • 9.5 Competitive heatmap
    • 9.6 Top player positioning, 2022

  • 10 COMPANY PROFILES

    • 10.1 Freenome Holdings, Inc
      • 10.1.1 Company overview
      • 10.1.2 Key executives
      • 10.1.3 Company snapshot
      • 10.1.4 Operating business segments
      • 10.1.5 Product portfolio
      • 10.1.6 Key strategic moves and developments
    • 10.2 Natera, Inc
      • 10.2.1 Company overview
      • 10.2.2 Key executives
      • 10.2.3 Company snapshot
      • 10.2.4 Operating business segments
      • 10.2.5 Product portfolio
      • 10.2.6 Business performance
      • 10.2.7 Key strategic moves and developments
    • 10.3 Agilent Technologies, Inc
      • 10.3.1 Company overview
      • 10.3.2 Key executives
      • 10.3.3 Company snapshot
      • 10.3.4 Operating business segments
      • 10.3.5 Product portfolio
      • 10.3.6 Business performance
      • 10.3.7 Key strategic moves and developments
    • 10.4 Exact Sciences Corporation
      • 10.4.1 Company overview
      • 10.4.2 Key executives
      • 10.4.3 Company snapshot
      • 10.4.4 Operating business segments
      • 10.4.5 Product portfolio
      • 10.4.6 Business performance
      • 10.4.7 Key strategic moves and developments
    • 10.5 Illumina, Inc
      • 10.5.1 Company overview
      • 10.5.2 Key executives
      • 10.5.3 Company snapshot
      • 10.5.4 Operating business segments
      • 10.5.5 Product portfolio
      • 10.5.6 Business performance
      • 10.5.7 Key strategic moves and developments
    • 10.6 F. Hoffmann-La Roche Ltd
      • 10.6.1 Company overview
      • 10.6.2 Key executives
      • 10.6.3 Company snapshot
      • 10.6.4 Operating business segments
      • 10.6.5 Product portfolio
      • 10.6.6 Business performance
      • 10.6.7 Key strategic moves and developments
    • 10.7 Guardant Health
      • 10.7.1 Company overview
      • 10.7.2 Key executives
      • 10.7.3 Company snapshot
      • 10.7.4 Operating business segments
      • 10.7.5 Product portfolio
      • 10.7.6 Business performance
      • 10.7.7 Key strategic moves and developments
    • 10.8 InterVenn Biosciences
      • 10.8.1 Company overview
      • 10.8.2 Key executives
      • 10.8.3 Company snapshot
      • 10.8.4 Operating business segments
      • 10.8.5 Product portfolio
      • 10.8.6 Key strategic moves and developments
    • 10.9 Thermo Fisher Scientific, Inc
      • 10.9.1 Company overview
      • 10.9.2 Key executives
      • 10.9.3 Company snapshot
      • 10.9.4 Operating business segments
      • 10.9.5 Product portfolio
      • 10.9.6 Business performance
      • 10.9.7 Key strategic moves and developments
    • 10.10 Invitae Corporation
      • 10.10.1 Company overview
      • 10.10.2 Key executives
      • 10.10.3 Company snapshot
      • 10.10.4 Operating business segments
      • 10.10.5 Product portfolio
      • 10.10.6 Business performance
      • 10.10.7 Key strategic moves and developments
    • 10.11 NeoGenomics Laboratories
      • 10.11.1 Company overview
      • 10.11.2 Key executives
      • 10.11.3 Company snapshot
      • 10.11.4 Operating business segments
      • 10.11.5 Product portfolio
      • 10.11.6 Business performance
      • 10.11.7 Key strategic moves and developments

価格：USD 3,840
569,626円 もしくは部分購入
適用レート
1 USD = 148.34円
※稀に出版元により価格が改定されている場合がございます。
contact
© 2023 ShareFair Inc.